Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (721)	5/5/1998 5:32:00 PM
From: Tom Caruthers	Read Replies (1) \| Respond to of 2135

Phil, I am sorry to hear about your wife. There is no question about it, everyone needs to make their own decisions about when to buy and sell. I was not saying that people should not buy or should not sell. What I was saying is that there is more at stake here than just money. Do what you want with the stock. Don't forget that this drug, whenever it may actually go to clinical trials, will be on a fast track for FDA approval. As a lead priority for the NCI, this is not one of those drugs that will get lost in a sea of paperwork. Also, the clinical trials may not take as long as everyone expects....if these peptides actually work, there will be a clear indications early on...compassionate use.... Anyway, I think the key to this company is to actually get enough protein to try this out in humans. Once that happens, I think that we will see things pick up quickly. That is the big question for me. Take care, Tom

To: Phil Cressman who wrote (721)	5/5/1998 7:15:00 PM
From: margaret foley	Respond to of 2135

Phil, Sorry about the loss of your wife. Your post provides honest guidance to many investors on these posts. However, on the network news this evening, the possibility of earlier human studies in this type of therapy might not be as impossible as most of us think. It was suggested that due to overwhelming response from friends, families and patients, the lines were jammed at the Cancer Institute(?or American Cancer Society) and also congressional representatives have been contacted by many constituents. Clearly new studies and pressure help Congress to reconsider issues and it was suggested that writing and/or calling, and emailing our congressional representatives might speed this research on humans along. All the best, Margaret